Fenwick Represents Perella Weinberg Partners in Penumbra's $14.5B Acquisition by Boston Scientific

Fenwick is representing Perella Weinberg Partners, exclusive financial advisor to Penumbra, Inc., (NYSE: PEN), in Penumbra's pending acquisition by Boston Scientific Corporation (NYSE: BSX). Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.

The acquisition of Penumbra will expand Boston Scientific's cardiovascular portfolio. The transaction is expected to be completed in 2026, subject to receipt of Penumbra's stockholder approval and the satisfaction of other customary closing conditions. More information can be obtained from the transaction announcement.

The Fenwick transaction team includes corporate partners Doug Cogen and David Michaels and associate Rob O'Connor.